Therapy Name | PDR001 + LCL161 |
Therapy Description |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LCL161 | SMAC Mimetic 8 | LCL161 is a SMAC mimetic that inhibits Inhibitor of Apoptosis Protein (IAP) family proteins, potentially leading to increased tumor cell death (PMID: 21681929, PMID: 24976294). | ||
PDR001 | Spartalizumab | Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 | Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT03111992 | Phase I | PDR001 + LCL161 PDR001 + CJM112 PDR001 | Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma | Recruiting |
NCT02890069 | Phase I | PDR001 + LCL161 PDR001 + Everolimus PDR001 + Panobinostat | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Recruiting |